TransMedics (Nasdaq:TMDX) received FDA investigational device exemption (IDE) for its next-generation OCS ENHANCE Heart trial.
Please provide your email address to receive an email when new articles are posted on . A cardiac transport system for donor hearts was associated with better 1-year outcomes for recipients compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results